MedTrace Logo

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

NCT04873323 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-02-28

No results posted yet for this study

Summary

A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

TS-142

Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period

DRUG

Moxifloxacin

Single dose of moxifloxacin 400 mg in the morning under fasting in each period

DRUG

Placebo

Single dose of TS-142 placebo in the morning under fasting in each period

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Direcoter · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2021-09-28
Completion
2021-09-28

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873323 on ClinicalTrials.gov